genia tagger: 109('restriction', 2)
('1\\.5iqr', 2)
('alleles', 2)
('jak2', 2)
('human', 2)
('papillary', 14)
('regions', 13)
('22', 14)
('kinase', 2)
('rnasea', 2)
('enzyme', 2)
('runx1', 2)
('black', 4)
('4', 150)
('marks', 2)
('\\.', 507)
('allele', 28)
('\\,', 584)
('suppressor', 6)
('\\(', 315)
('\\)', 315)
('murine', 2)
('chromatin', 2)
('output\\.', 2)
('1\xe2\x80\x936', 8)
('rad51', 2)
('deficient', 4)
('upd', 135)
('susceptibilities', 1)
('proteins', 8)
('185delag', 8)
('large', 13)
('x', 137)
('wt1', 2)
('cebpa', 2)
('q-arm', 2)
('genomic', 55)
('6174delt', 4)
('nuclear', 2)
('ovarian', 66)
('3', 187)
('critical', 2)
('mutation', 94)
('stata', 4)
('tables', 2)
('genes', 24)
('fig\\.', 12)
('box', 4)
('39', 10)
('k', 89)
('7', 127)
('tumor', 131)
('products', 3)
('double-strand', 2)
('gene', 99)
('cancer', 65)
('mutations', 42)
('locus', 12)
('8765delag', 2)
('wild-type', 2)
('table', 15)
('dna', 57)
('loh', 68)
('autosomal', 6)
('rb1', 6)
('l598x', 2)
('2', 270)
('6', 97)
('tyrosine', 2)
('brca1', 51)
('brca2', 42)
('p-arm', 2)
('representative', 4)
('cases', 87)
('case', 110)
('13', 42)
('2699delt', 2)
('tp53', 6)
('50k', 9)
('17', 45)
('cells', 11)
('grey', 2)
('iqr', 4)
('patient\xe2\x80\x99s', 1)
('brca', 237)
('cnag', 6)
('and', 239)
('figure', 18)
('loci', 16)
('proteinase', 2)
('chromosome', 115)
('repair-recombination', 2)
('40', 10)
('1', 385)
('serous', 14)
('5', 120)
('genome', 46)
('hatch', 2)
('figures', 4)
('germline', 21)
('elements', 2)
('chromosomes', 30)
('normal', 56)
('mapping', 5)
('xbai', 2)
('snp', 21)
('machinery', 2)
('\xe2\x80\x9csecond-hit\xe2\x80\x9d', 2)
('flt3', 2)


spacy + metamap: 498('limited', 2)
('alleles', 2)
('serous tumors', 1)
('locations', 7)
('four', 4)
('surgical', 6)
('systemic', 4)
('neoplastic transformation', 2)
('chromosomal rearrangements', 2)
('ptt', 2)
('integrity', 3)
('amplification', 22)
('tx', 2)
('technique', 1)
('genetic profile', 1)
('autosomal', 6)
('hemizygous', 12)
('marks', 2)
('peripheral blood samples', 2)
('heterogeneity', 4)
('risk', 4)
('brca2 proteins', 2)
('cellular', 4)
('difference', 6)
('entire', 23)
('level', 8)
('deficient', 4)
('cause', 9)
('upd', 135)
('tokyo', 2)
('large', 13)
('solid', 2)
('allelic loss', 2)
('inversions', 1)
('occurrence', 5)
('serous epithelial ovarian cancer', 6)
('ovarian cancer', 58)
('defect', 4)
('past', 2)
('noise', 2)
('dna repair', 6)
('run', 14)
('blue', 16)
('primer', 2)
('sum', 13)
('selected', 2)
('ovarian', 66)
('hereditary', 3)
('number data', 3)
('decade', 1)
('patient characteristics', 4)
('3c', 4)
('increasing', 1)
('contrast', 4)
('3d', 4)
('degree', 18)
('genes', 24)
('commercial', 6)
('understanding', 1)
('ethanol', 2)
('change', 29)
('box', 4)
('institutional review board', 2)
('medical center', 2)
('daughter', 2)
('involved', 10)
('study', 8)
('larger', 2)
('reports', 5)
('somatic', 8)
('products', 3)
('genome', 46)
('gene', 99)
('changes', 19)
('total', 6)
('risk subpopulation', 1)
('use', 17)
('solid tumors', 1)
('dna', 57)
('lifetime risk', 1)
('two', 10)
('mutation analysis', 4)
('eleven', 4)
('call', 10)
('panel', 2)
('type', 36)
('homologous recombination', 6)
('more', 11)
('peripheral blood', 6)
('0\\%', 56)
('outpatient', 2)
('visual', 8)
('known', 2)
('cases', 87)
('supplemental', 6)
('women', 6)
('high', 29)
('mg', 4)
('mb', 137)
('science', 2)
('mitotic recombination', 4)
('nine', 6)
('three', 10)
('spontaneous', 2)
('example', 4)
('10\\%', 1)
('control', 1)
('process', 16)
('sample', 9)
('germline mutation', 5)
('axis', 4)
('pink', 8)
('end', 30)
('discussion', 2)
('six', 17)
('genomes', 4)
('adjacent', 8)
('subtypes', 1)
('outlier', 2)
('chromosomal breakage', 8)
('blocks', 4)
('mapping', 5)
('blood', 8)
('snp', 21)
('data', 17)
('types', 29)
('third', 2)
('recombination', 24)
('lines', 2)
('brca1 mutation', 11)
('green', 14)
('order', 3)
('ashkenazi jewish', 2)
('rad51', 2)
('years', 4)
('group', 8)
('23', 8)
('pcr', 4)
('platform', 6)
('subpopulation', 1)
('fig', 46)
('precipitate', 2)
('genomic stability', 2)
('non', 11)
('greater', 12)
('break', 16)
('feature', 2)
('dataset', 2)
('matched', 7)
('restriction enzyme', 2)
('sister chromatid', 2)
('university', 4)
('proteins', 8)
('magnitude', 2)
('instability', 29)
('subset', 2)
('founder mutation', 2)
('cytogenetic', 1)
('exons', 2)
('myeloproliferative disorders', 2)
('abnormal', 36)
('related', 1)
('coding region', 4)
('deficiency', 4)
('frequency', 29)
('laboratory', 8)
('event', 40)
('ovarian carcinomas', 3)
('discrete', 12)
('20\\%', 8)
('research', 2)
('increase', 8)
('college health', 2)
('evaluation', 2)
('clone', 2)
('red', 95)
('descendents', 2)
('mechanisms', 4)
('standard', 2)
('homologous', 8)
('chromosomal', 17)
('mutation carrier', 15)
('brca genes', 4)
('protein truncation', 2)
('carboplatin\\/paclitaxel', 4)
('transition', 4)
('length', 4)
('top', 4)
('frequent', 17)
('first', 3)
('cellular proliferation', 1)
('number', 75)
('one', 38)
('defects', 2)
('family history', 2)
('array', 24)
('genetic abnormality', 1)
('santa clara', 2)
('findings', 2)
('introduction', 1)
('leading', 4)
('3 stage', 4)
('approximately', 4)
('station', 2)
('uniparental disomy', 16)
('genomic dna', 5)
('molecular', 5)
('residual disease', 4)
('brca1', 51)
('tumor suppressor genes', 6)
('brca2', 42)
('adaptor', 2)
('part', 3)
('copy', 66)
('percentage', 13)
('population', 3)
('wide', 8)
('roles', 2)
('isolation', 2)
('grey', 2)
('significantly high', 6)
('c all', 2)
('regulator', 2)
('patients', 54)
('snp array', 5)
('college', 4)
('prone', 2)
('mini', 2)
('suspicious', 4)
('spectrum', 6)
('inpatient', 2)
('30\\%', 4)
('sporadic', 66)
('abnormalities', 24)
('100\\%', 24)
('quartile', 4)
('corp\\.', 2)
('mechanism', 6)
('majority', 5)
('edge', 2)
('dna sequencing', 2)
('hatch', 2)
('objective', 1)
('interquartile range', 2)
('multiple', 5)
('supplementary material', 2)
('normal', 56)
('buffer', 4)
('telomere', 24)
('cell cycle', 4)
('genetic changes', 9)
('nuclear proteins', 2)
('average', 2)
('graphs', 4)
('los angeles', 2)
('duplication', 4)
('dot', 2)
('mitotic cell cycle', 2)
('random', 2)
('hematologic', 2)
('carcinogen', 9)
('papillary', 14)
('line', 33)
('fifth', 1)
('complex karyotype', 1)
('based', 14)
('proportion', 1)
('black', 4)
('inherited', 1)
('various', 4)
('mortality', 1)
('means', 2)
('overall', 4)
('single nucleotide polymorphisms', 1)
('greater than', 6)
('heterozygosity', 8)
('negative', 4)
('report', 5)
('dna recombination', 2)
('areas', 24)
('bar', 30)
('tumors', 106)
('median', 36)
('alteration', 26)
('common', 4)
('activity', 2)
('wt1', 2)
('bars', 24)
('reference', 2)
('testing', 8)
('approved protocol', 2)
('individual', 2)
('serous ovarian cancer', 3)
('result', 17)
('genomic', 55)
('surgery', 8)
('arm', 4)
('subject', 2)
('inappropriate', 2)
('review', 4)
('carcinomas', 5)
('molecular pathway', 4)
('percentiles', 2)
('identification', 3)
('new technology', 1)
('consecutive', 2)
('vertical', 6)
('transcriptional regulation', 2)
('snps', 3)
('cancer related', 1)
('analyzer', 2)
('white', 2)
('whisker', 4)
('homozygosity', 2)
('deregulation', 1)
('region', 20)
('density', 1)
('whole', 1)
('groups', 4)
('cancer', 65)
('point', 6)
('copy number', 62)
('ca', 591)
('mutations', 42)
('65', 6)
('table', 15)
('platinum', 4)
('adjuvant chemotherapy', 4)
('40\\%', 4)
('copies', 4)
('genetic', 62)
('direction', 2)
('great', 16)
('ovarian cancer predisposition', 2)
('representative', 4)
('spin', 2)
('protocols', 2)
('case', 110)
('exception', 12)
('novel', 2)
('frozen', 3)
('appearance', 2)
('single', 4)
('error', 2)
('31', 12)
('characteristics', 6)
('iv', 68)
('tissue', 6)
('tumor cell', 2)
('pathology', 2)
('technology', 5)
('different', 5)
('baseline', 6)
('recurrent', 4)
('elevated', 2)
('complex', 5)
('deletion', 56)
('high frequency', 2)
('several', 8)
('events', 34)
('higher', 20)
('status', 2)
('proteinase k', 2)
('chloroform', 2)
('purpose', 1)
('v8', 2)
('lower', 8)
('abnormality', 10)
('center', 6)
('analysis', 12)
('patterns', 11)
('materials', 5)
('machinery', 2)
('left', 4)
('protocol', 8)
('gynecologic malignancies', 1)
('50\\%', 11)
('human', 2)
('extraction method', 2)
('ng', 353)
('tables', 2)
('conclusions', 1)
('brca2 mutation', 13)
('demographic', 2)
('operative reports', 2)
('location', 11)
('allele', 28)
('structural', 2)
('remaining', 9)
('hybridization', 4)
('murine', 2)
('homozygous', 6)
('increased', 6)
('survival', 4)
('hereditary predisposition', 1)
('experimental design', 1)
('x chromosome', 8)
('finding', 4)
('background', 6)
('unique', 4)
('loss', 17)
('entire chromosome', 12)
('55', 2)
('signal', 4)
('less than', 4)
('specific', 18)
('either', 4)
('output', 4)
('function', 4)
('cellular process', 2)
('array comparative genomic hybridization', 2)
('methods', 1)
('gel electrophoresis', 4)
('growth', 2)
('chromosomes', 30)
('runx1 gene', 2)
('jak2 tyrosine kinase', 2)
('gross', 2)
('bottom', 2)
('critical', 2)
('mutation', 94)
('data analysis', 2)
('patient', 67)
('90\\%', 4)
('histologic', 2)
('serous ovarian carcinomas', 2)
('recombinations', 2)
('diploid', 12)
('chromosomal instability', 2)
('stage', 22)
('comparison', 4)
('column', 2)
('carcinogenesis', 3)
('months', 16)
('tumor', 131)
('range', 39)
('os', 210)
('block', 4)
('presence', 1)
('locus', 12)
('cancer cells', 3)
('female', 1)
('genetic abnormalities', 2)
('additional', 12)
('area', 29)
('loh', 68)
('clinical', 10)
('charts', 2)
('medical records', 2)
('link', 2)
('gain', 1)
('technologies', 2)
('truncation', 2)
('double strand', 4)
('regimen', 4)
('cells', 11)
('homologous recombination dna repair', 2)
('ovarian cancers', 16)
('genomic instability', 8)
('allelic imbalance', 1)
('distribution', 6)
('similar', 4)
('associated', 82)
('fusions', 2)
('genetic alteration', 21)
('stage iiic', 4)
('right', 2)
('chromosome number', 1)
('lysis', 14)
('chromosome', 115)
('translocations', 5)
('variety', 1)
('acute myeloid leukemia', 2)
('percent', 19)
('detail', 12)
('duplications', 1)
('adjuvant', 4)
('serous', 14)
('role', 5)
('details', 8)
('phenol', 2)
('heterozygous', 2)
('germline', 21)
('elements', 2)
('very rare', 4)
('chromosomal abnormalities', 1)
('whiskers', 2)
('important', 9)
('pathways', 5)
('coverage', 2)
('genetic change', 11)
('variable', 2)
('age', 58)
('pfs', 4)
('diagnosis', 4)
('time', 7)
('fresh', 3)
('brca gene', 5)


total: 559('limited', 2)
('alleles', 2)
('serous tumors', 1)
('locations', 7)
('four', 4)
('surgical', 6)
('systemic', 4)
('neoplastic transformation', 2)
('chromosomal rearrangements', 2)
('ptt', 2)
('integrity', 3)
('amplification', 22)
('tx', 2)
('technique', 1)
('genetic profile', 1)
('autosomal', 6)
('hemizygous', 12)
('marks', 2)
('peripheral blood samples', 2)
('heterogeneity', 4)
('risk', 4)
('brca2 proteins', 2)
('1\xe2\x80\x936', 8)
('cellular', 4)
('difference', 6)
('multiple', 5)
('entire', 23)
('level', 8)
('deficient', 4)
('cause', 9)
('upd', 135)
('mb', 137)
('6174delt', 4)
('large', 13)
('frozen', 3)
('allelic loss', 2)
('inversions', 1)
('cebpa', 2)
('occurrence', 5)
('serous epithelial ovarian cancer', 6)
('ovarian cancer', 58)
('defect', 4)
('past', 2)
('noise', 2)
('dna repair', 6)
('run', 14)
('blue', 16)
('primer', 2)
('sum', 13)
('selected', 2)
('ovarian', 66)
('hereditary', 3)
('number data', 3)
('decade', 1)
('patient characteristics', 4)
('3c', 4)
('increasing', 1)
('contrast', 4)
('3d', 4)
('degree', 18)
('genes', 24)
('commercial', 6)
('understanding', 1)
('ethanol', 2)
('change', 29)
('box', 4)
('institutional review board', 2)
('39', 10)
('daughter', 2)
('involved', 10)
('study', 8)
('larger', 2)
('reports', 5)
('somatic', 8)
('products', 3)
('gene', 99)
('changes', 19)
('total', 6)
('risk subpopulation', 1)
('use', 17)
('solid tumors', 1)
('dna', 57)
('lifetime risk', 1)
('two', 10)
('mutation analysis', 4)
('eleven', 4)
('call', 10)
('6', 97)
('panel', 2)
('type', 36)
('homologous recombination', 6)
('more', 11)
('brca genes', 4)
('0\\%', 56)
('outpatient', 2)
('visual', 8)
('known', 2)
('cases', 87)
('supplemental', 6)
('women', 6)
('sample', 9)
('mg', 4)
('2699delt', 2)
('tp53', 6)
('tokyo', 2)
('science', 2)
('mitotic recombination', 4)
('nine', 6)
('three', 10)
('brca', 237)
('spontaneous', 2)
('example', 4)
('10\\%', 1)
('cnag', 6)
('control', 1)
('figure', 18)
('process', 16)
('loci', 16)
('high', 29)
('germline mutation', 5)
('axis', 4)
('pink', 8)
('end', 30)
('discussion', 2)
('six', 17)
('genomes', 4)
('regions', 13)
('adjacent', 8)
('blocks', 4)
('outlier', 2)
('chromosomal breakage', 8)
('mapping', 5)
('blood', 8)
('snp', 21)
('data', 17)
('types', 29)
('third', 2)
('recombination', 24)
('lines', 2)
('brca1 mutation', 11)
('green', 14)
('\xe2\x80\x9csecond-hit\xe2\x80\x9d', 2)
('order', 3)
('restriction', 2)
('ashkenazi jewish', 2)
('rad51', 2)
('years', 4)
('1', 385)
('group', 8)
('22', 14)
('23', 8)
('pcr', 4)
('rnasea', 2)
('platform', 6)
('subpopulation', 1)
('fig', 46)
('p-arm', 2)
('precipitate', 2)
('suppressor', 6)
('genomic stability', 2)
('chromatin', 2)
('greater', 12)
('break', 16)
('feature', 2)
('dataset', 2)
('matched', 7)
('restriction enzyme', 2)
('sister chromatid', 2)
('university', 4)
('proteins', 8)
('185delag', 8)
('magnitude', 2)
('instability', 29)
('subset', 2)
('founder mutation', 2)
('cytogenetic', 1)
('hereditary predisposition', 1)
('myeloproliferative disorders', 2)
('abnormal', 36)
('related', 1)
('coding region', 4)
('deficiency', 4)
('frequency', 29)
('laboratory', 8)
('event', 40)
('ovarian carcinomas', 3)
('discrete', 12)
('20\\%', 8)
('research', 2)
('increase', 8)
('college health', 2)
('runx1', 2)
('7', 127)
('evaluation', 2)
('clone', 2)
('red', 95)
('descendents', 2)
('mechanisms', 4)
('standard', 2)
('homologous', 8)
('chromosomal', 17)
('mutation carrier', 15)
('additional', 12)
('peripheral blood', 6)
('protein truncation', 2)
('carboplatin\\/paclitaxel', 4)
('transition', 4)
('length', 4)
('top', 4)
('frequent', 17)
('first', 3)
('cellular proliferation', 1)
('number', 75)
('one', 38)
('defects', 2)
('family history', 2)
('wild-type', 2)
('array', 24)
('genetic abnormality', 1)
('santa clara', 2)
('findings', 2)
('introduction', 1)
('leading', 4)
('3 stage', 4)
('approximately', 4)
('l598x', 2)
('station', 2)
('uniparental disomy', 16)
('genomic dna', 5)
('molecular', 5)
('residual disease', 4)
('brca1', 51)
('tumor suppressor genes', 6)
('brca2', 42)
('adaptor', 2)
('part', 3)
('copy', 66)
('percentage', 13)
('population', 3)
('wide', 8)
('13', 42)
('roles', 2)
('isolation', 2)
('grey', 2)
('significantly high', 6)
('c all', 2)
('regulator', 2)
('patients', 54)
('snp array', 5)
('college', 4)
('prone', 2)
('and', 239)
('mini', 2)
('suspicious', 4)
('spectrum', 6)
('inpatient', 2)
('30\\%', 4)
('sporadic', 66)
('abnormalities', 24)
('100\\%', 24)
('quartile', 4)
('repair-recombination', 2)
('corp\\.', 2)
('mechanism', 6)
('majority', 5)
('edge', 2)
('dna sequencing', 2)
('hatch', 2)
('objective', 1)
('interquartile range', 2)
('chromosomes', 30)
('supplementary material', 2)
('normal', 56)
('buffer', 4)
('telomere', 24)
('cell cycle', 4)
('genetic changes', 9)
('nuclear proteins', 2)
('average', 2)
('graphs', 4)
('los angeles', 2)
('duplication', 4)
('flt3', 2)
('dot', 2)
('mitotic cell cycle', 2)
('1\\.5iqr', 2)
('random', 2)
('hematologic', 2)
('carcinogen', 9)
('papillary', 14)
('line', 33)
('fifth', 1)
('complex karyotype', 1)
('based', 14)
('proportion', 1)
('kinase', 2)
('enzyme', 2)
('black', 4)
('inherited', 1)
('various', 4)
('mortality', 1)
('new technology', 1)
('means', 2)
('overall', 4)
('single nucleotide polymorphisms', 1)
('greater than', 6)
('heterozygosity', 8)
('negative', 4)
('report', 5)
('2', 270)
('dna recombination', 2)
('areas', 24)
('bar', 30)
('17', 45)
('tumors', 106)
('median', 36)
('alteration', 26)
('common', 4)
('activity', 2)
('x', 137)
('wt1', 2)
('bars', 24)
('reference', 2)
('testing', 8)
('approved protocol', 2)
('individual', 2)
('serous ovarian cancer', 3)
('result', 17)
('genomic', 55)
('surgery', 8)
('genomic instability', 8)
('arm', 4)
('subject', 2)
('inappropriate', 2)
('nuclear', 2)
('review', 4)
('carcinomas', 5)
('molecular pathway', 4)
('3', 187)
('percentiles', 2)
('identification', 3)
('stata', 4)
('consecutive', 2)
('vertical', 6)
('transcriptional regulation', 2)
('snps', 3)
('cancer related', 1)
('analyzer', 2)
('fig\\.', 12)
('white', 2)
('whisker', 4)
('homozygosity', 2)
('deregulation', 1)
('region', 20)
('density', 1)
('figures', 4)
('double-strand', 2)
('whole', 1)
('groups', 4)
('cancer', 65)
('point', 6)
('copy number', 62)
('ca', 591)
('mutations', 42)
('65', 6)
('table', 15)
('platinum', 4)
('details', 8)
('adjuvant chemotherapy', 4)
('40\\%', 4)
('copies', 4)
('8765delag', 2)
('genetic', 62)
('location', 11)
('direction', 2)
('medical center', 2)
('ovarian cancer predisposition', 2)
('representative', 4)
('spin', 2)
('protocols', 2)
('case', 110)
('exception', 12)
('novel', 2)
('50k', 9)
('solid', 2)
('appearance', 2)
('stage iiic', 4)
('error', 2)
('hybridization', 4)
('k', 89)
('characteristics', 6)
('non', 11)
('iv', 68)
('tissue', 6)
('tumor cell', 2)
('pathology', 2)
('technology', 5)
('increased', 6)
('different', 5)
('baseline', 6)
('recurrent', 4)
('elevated', 2)
('complex', 5)
('deletion', 56)
('high frequency', 2)
('several', 8)
('events', 34)
('higher', 20)
('status', 2)
('proteinase k', 2)
('chloroform', 2)
('xbai', 2)
('purpose', 1)
('v8', 2)
('lower', 8)
('abnormality', 10)
('center', 6)
('analysis', 12)
('patterns', 11)
('materials', 5)
('31', 12)
('machinery', 2)
('left', 4)
('protocol', 8)
('gynecologic malignancies', 1)
('50\\%', 11)
('jak2', 2)
('human', 2)
('extraction method', 2)
('ng', 353)
('tables', 2)
('conclusions', 1)
('brca2 mutation', 13)
('demographic', 2)
('operative reports', 2)
('4', 150)
('\\.', 507)
('allele', 28)
('\\,', 584)
('structural', 2)
('remaining', 9)
('\\(', 315)
('\\)', 315)
('murine', 2)
('homozygous', 6)
('output\\.', 2)
('survival', 4)
('experimental design', 1)
('x chromosome', 8)
('finding', 4)
('background', 6)
('unique', 4)
('loss', 17)
('entire chromosome', 12)
('55', 2)
('signal', 4)
('susceptibilities', 1)
('less than', 4)
('specific', 18)
('either', 4)
('output', 4)
('function', 4)
('cellular process', 2)
('array comparative genomic hybridization', 2)
('methods', 1)
('germline', 21)
('gel electrophoresis', 4)
('growth', 2)
('subtypes', 1)
('5', 120)
('jak2 tyrosine kinase', 2)
('gross', 2)
('bottom', 2)
('critical', 2)
('mutation', 94)
('data analysis', 2)
('patient', 67)
('90\\%', 4)
('histologic', 2)
('serous ovarian carcinomas', 2)
('recombinations', 2)
('diploid', 12)
('chromosomal instability', 2)
('stage', 22)
('comparison', 4)
('column', 2)
('carcinogenesis', 3)
('months', 16)
('tumor', 131)
('range', 39)
('os', 210)
('block', 4)
('presence', 1)
('locus', 12)
('cancer cells', 3)
('rb1', 6)
('female', 1)
('genetic abnormalities', 2)
('exons', 2)
('area', 29)
('loh', 68)
('clinical', 10)
('charts', 2)
('tyrosine', 2)
('medical records', 2)
('great', 16)
('link', 2)
('gain', 1)
('technologies', 2)
('truncation', 2)
('double strand', 4)
('regimen', 4)
('cells', 11)
('homologous recombination dna repair', 2)
('ovarian cancers', 16)
('iqr', 4)
('allelic imbalance', 1)
('patient\xe2\x80\x99s', 1)
('distribution', 6)
('similar', 4)
('associated', 82)
('fusions', 2)
('genetic alteration', 21)
('single', 4)
('right', 2)
('chromosome number', 1)
('lysis', 14)
('proteinase', 2)
('chromosome', 115)
('runx1 gene', 2)
('translocations', 5)
('variety', 1)
('acute myeloid leukemia', 2)
('percent', 19)
('detail', 12)
('40', 10)
('duplications', 1)
('adjuvant', 4)
('serous', 14)
('role', 5)
('genome', 46)
('phenol', 2)
('heterozygous', 2)
('q-arm', 2)
('elements', 2)
('very rare', 4)
('chromosomal abnormalities', 1)
('whiskers', 2)
('important', 9)
('pathways', 5)
('coverage', 2)
('genetic change', 11)
('variable', 2)
('age', 58)
('pfs', 4)
('diagnosis', 4)
('time', 7)
('fresh', 3)
('brca gene', 5)
